Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Jeju Semiconductor (080220) – Submission of Audit Report / 2024-03-20

Posted on March 20, 2024August 3, 2026 By K-STOCK Editor No Comments on [Disclosure] Jeju Semiconductor (080220) – Submission of Audit Report / 2024-03-20

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Jeju Semiconductor received and submitted its external audit report for FY2023, obtaining an ‘Unqualified’ audit opinion for both consolidated and separate financial statements.

📊 Key Disclosure Contents & Major Figures

1. Audit Opinion & External Audit Overview

  • External Auditor: Daehyun Accounting Corp.
  • Audit Report Receipt Date: March 20, 2024
  • Consolidated Audit Opinion: Unqualified (Prior FY: Unqualified)
  • Separate Audit Opinion: Unqualified (Prior FY: Unqualified)
  • Going Concern Uncertainty: N/A (Both consolidated and separate)
  • Internal Accounting Control System Adverse Opinion or Material Weakness: N/A

2. Major Figures in Consolidated Financial Statements

  • Total Assets: KRW 198.67B (KRW 198,673,382,796) / (Prior FY: KRW 175.99B)
  • Total Liabilities: KRW 40.10B (KRW 40,104,977,649) / (Prior FY: KRW 33.30B)
  • Total Equity: KRW 158.57B (KRW 158,568,405,147) / (Prior FY: KRW 142.70B)
  • Capital Stock: KRW 17.37B (KRW 17,371,416,500) / (Prior FY: KRW 17.37B)
  • Revenue: KRW 145.90B (KRW 145,899,793,599) / (Prior FY: KRW 158.26B)
  • Operating Profit: KRW 17.84B (KRW 17,838,425,308) / (Prior FY: KRW 26.32B)
  • Income Before Income Taxes: KRW 22.01B (KRW 22,007,168,740) / (Prior FY: KRW 31.13B)
  • Net Income: KRW 16.92B (KRW 16,919,765,330) / (Prior FY: KRW 24.71B)
  • Net Income Attributable to Owners of Parent: KRW 16.72B (KRW 16,724,869,342) / (Prior FY: KRW 24.33B)
  • Number of Consolidated Subsidiaries: 2 (Major Subsidiaries: 0)

3. Major Figures in Separate Financial Statements

  • Total Assets: KRW 195.91B (KRW 195,907,390,918) / (Prior FY: KRW 175.62B)
  • Total Liabilities: KRW 38.37B (KRW 38,370,467,192) / (Prior FY: KRW 31.05B)
  • Total Equity: KRW 157.54B (KRW 157,536,923,726) / (Prior FY: KRW 144.58B)
  • Capital Stock: KRW 17.37B (KRW 17,371,416,500) / (Prior FY: KRW 17.37B)
  • Revenue: KRW 145.90B (KRW 145,899,793,599) / (Prior FY: KRW 158.26B)
  • Operating Profit: KRW 17.51B (KRW 17,511,970,460) / (Prior FY: KRW 26.07B)
  • Income Before Income Taxes: KRW 19.14B (KRW 19,137,560,094) / (Prior FY: KRW 31.38B)
  • Net Income: KRW 13.53B (KRW 13,529,201,527) / (Prior FY: KRW 23.67B)

4. Other Reference Matters & Financial Stability Metrics

  • This filing serves as a correction disclosure for previous filings dated Feb 28, 2024 (30% change in revenue/profitability) and Mar 05, 2024 (Notice of AGM).
  • Financial statements in the audit report may change upon approval at the general shareholders’ meeting.
  • Capital Impairment Ratio: N/A (Total Equity: KRW 157.32B / Capital Stock: KRW 17.37B)
  • Impairment Loss Ratio Exceeding 50%: No

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of External Audit Opinion and Shareholder Meeting Approval

Through the submission of this audit report, an unqualified audit opinion and the audited financial figures for FY2023 have been officially reported. Because the financial statements in the audit report are subject to change during the general shareholders’ meeting approval process, checking whether they are approved as submitted is important to confirm the final completion of the financial settlement procedure. Relevant details can be verified in subsequent disclosures such as the results of the general shareholders’ meeting and periodic reports including annual, semi-annual, or quarterly reports.

📢 Disclaimer & Source Notice

Fact Source: Financial Supervisory Service DART

Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] Hana Micron (067310) – Submission of Audit Report / 2024-03-20
Next Post: [Disclosure] Samsung Electro-Mechanics (009150) – Results of Annual General Meeting of Shareholders / 2024-03-20

Related Posts

[Disclosure] Hanwha Ocean (042660) – Provisional Financial Results (Fair Disclosure) / 2025-04-28 Disclosures
[Disclosure] SK Hynix (000660) – Decision on New Facility Investment / 2024-07-26 Semiconductors
[Disclosure] Daeduck Electronics (353200) – Provisional Operating Results (Consolidated Financial Basis) / 2026-07-31 Disclosures
[Disclosure] ALTEOGEN (196170) – Decision on Acquisition of Shares and Investment Certificates of Other Corporations / 2024-11-07 Disclosures
[Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports / 2025-04-11 Disclosures
[Disclosure] Wonik IPS (240810) – Setting of Record Date or Period for Suspension of Entry of Change in Shareholders’ Register / 2026-07-24 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme